Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

摘要

The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.